Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 16, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy.

Manisha Palta1, Christopher G Morris, Stephen R Grobmyer

  • 1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA.

Cancer
|February 18, 2010
PubMed
Summary

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of 5- Versus 10-Fraction Radiation Therapy for Hepatocellular Carcinoma at a Veteran Affairs Hospital.

International journal of radiation oncology, biology, physics·2026
Same author

Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Toxicity of Ablative Radiation Therapy in the Management of Patients with Child-Pugh B/C Liver Function and Unresectable Hepatocellular Carcinoma (HCC).

Cancers·2026
Same author

Design and Implementation of Novel Internal Mini Fellowship Concentrations Within a Radiation Oncology Residency Program.

International journal of radiation oncology, biology, physics·2026
Same author

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.

International journal of particle therapy·2026
Same author

Accuracy of Photon Dose Calculation on Photon-Counting Computed Tomography-A Comparison Study Based on Virtual Monoenergetic and Electron Density (Rho) Images for Pancreatic Cases.

Advances in radiation oncology·2026

Hyperfractionated and accelerated radiotherapy (HART) offers a promising treatment for rare angiosarcoma after breast-conserving therapy (BCT). This novel approach achieved high rates of local control and survival in a recent study.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Breast-conserving therapy (BCT) is standard for early breast cancer, but rare angiosarcomas can develop post-treatment.
  • Existing treatments for post-BCT angiosarcoma have shown limited success.
  • There is no established consensus for managing this rare malignancy.

Purpose of the Study:

  • To evaluate the long-term outcomes of hyperfractionated and accelerated radiotherapy (HART) for angiosarcoma developing after BCT.
  • To report on a novel therapeutic approach for a rare post-BCT complication.

Main Methods:

  • Retrospective review of 14 patients treated with HART, with or without surgery.
  • Treatment occurred at the University of Florida between November 1997 and March 2006.

Related Experiment Videos

Last Updated: Jun 16, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

  • Focus on angiosarcoma that developed subsequent to BCT.

    • Main Results:

    • Nine out of 14 patients remained disease-free for a median of 61 months post-HART.
    • Five patients experienced disease recurrence or progression, often with pre-existing pulmonary/mediastinal disease.
    • Two-year and five-year progression-free survival rates were 71% and 64%, respectively.
    • Overall and cause-specific survival rates were 86% at both 2 and 5 years.

    Conclusions:

    • HART, with or without surgery, appears to be the first approach yielding high local control and survival rates for post-BCT angiosarcoma.
    • The study suggests that the hyperfractionation and acceleration of radiotherapy contribute to the observed success.
    • This approach offers a potential new standard for managing this challenging condition.